Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 6/20 | 0.59 |
| ▸ | CES2 | O00748 | 3/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetamide SCHEMBL28865377 | 0.85 | MAPK1 (0.56) | HCAR3CES2CES1MAPTCYP1A2 | |
| Hydrochloric Acid SCHEMBL7428031 | 0.85 | HCAR3 (0.76) | HCAR3MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25351095 | 0.81 | HCAR3 (0.58) | HCAR3MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30370129 | 0.81 | HCAR3 (0.58) | HCAR3MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL989785 | 0.75 | CES2 (0.58) | HCAR3CES2CES1MAPTRECQL | |
| SCHEMBL4238591 | 0.74 | HCAR3 (1.00) | HCAR3 | |
| SCHEMBL12497325 | 0.74 | MAPT (0.67) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL103504 | 0.74 | HCAR3 (0.55) | HCAR3MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30274042 | 0.74 | HCAR3 (0.55) | HCAR3MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL989349 | 0.74 | MAPT (0.51) | HCAR3MAPTCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | HCAR3 3757/4885CES2 3750/4885CES1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.